Genentech, Inc.

Gilead Sciences, Inc.

F. Hoffmann-la Roche Ag

Genetech, Inc.

Piramed Limited

Vickie H Tsui

William John Watkins

Lan Jiang

Chandrasekar Venkataramani

Hong Yang

Darryl Kato

Juan A Guerrero

Devan Naduthambi

Tetsuya Kobayashi

Jonathan William Medley

David W Lin

Hang Chu

Scott E Lazerwith

Michael L Mitchell

Xiaofen Li

Xiaojing Wang

Neil H Squires

John Edward Knox, Jr

Bing-Yan Zhu

Daniel P Sutherlin

Alan G Olivero

Adrian Folkes

Georgette M Castanedo

Richard A Goldsmith

Shumei Wang

Simon Mathieu

Tim Heffron

Janet Gunzner

Jun Liang

Steven R Magnuson

Steven Huy Do

Aleksandr Kolesnikov

Christian Wiesmann

Andrew Sharpe

Minghua Sun

Birong Zhang

Simon Charles Goodacre

Karen Williams

Alastair James Hodges

Calum Macleod

Steven T Staben

Wendy Lee

Chudi Obioma Ndubaku

Richard Pastor

Irina Chuckowree

Nan Chi Wan

Calum MacLeod

Anna E Hurtley

Tae H Hwang

Zachary Newby

Jennafer Dotson

Tracy Bayliss

Toby Jonathan Blench

Qingming Zhu

Sally Oxenford

Kimberly Malesky

Tim Hancox

Yingjie Lai

Huiyong Hu

Mizio Matteucci

Stephen Joseph Shuttleworth

Zhaoyang Wen

Jeremy M Murray

Stephen Shuttleworth

Charles Ellwood

Ingrid Wertz

Robert Anthony Blake

Till Maurer

Paola Di Lello

Lionel Rouge

Lorna Kategaya

Christine Johanna Heideker

Jason Drummond

Kebing Yu

Christine Heideker

Ingrid E Wertz

Jason Jake Drummond

Jonathan W Medley

Christian Weismann

The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.

MCL1 inhibitors

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

MCL-1 inhibitors

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer. 

2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

USP7 inhibitor compounds and methods of use

Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and Ris a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Phosphoinositide 3-kinase inhibitor compounds and methods of use

5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

5-azaindazole compounds and methods of use

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy. 

Pyrazolopyridine compounds, compositions and methods of use

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazolo[3,4-c]pyridine compounds and methods of use

Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I. 

Azabenzothiazole compounds, compositions and methods of use

Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Growing community of inventors

Burlingame, CA, United States of America

Vickie H Tsui